Topas launches Phase IIa trial of celiac disease therapy

Topas Therapeutics has launched a Phase IIa clinical trial of TPM502 to treat patients with celiac disease, an autoimmune disorder.

The placebo-controlled, double-blind, randomised, multi-centre study will assess the tolerability, safety and pharmacodynamic effects of two TPM502 administrations in dose-escalating cohorts.